Lucia Trandafir
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 17, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Journal: The Prostate
Published: April 08, 2019
Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Journal: Anticancer research
Published: August 02, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Journal: OncoTargets and therapy
Published: January 22, 2016
Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
Journal: Cancer chemotherapy and pharmacology
Published: May 27, 2015
A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
Journal: Journal of clinical pharmacology
Published: May 13, 2015
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: December 17, 2013
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Journal: Investigational new drugs
Published: December 21, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026